Asset
EDRALBRUTINIB
TG Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03671590 | phase1 | terminated | 2018-09-10 | 2024-05-21 | TG Therapeutics, Inc. | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies |
FDA applications (0)
This company has no applications containing this asset.